SNX27 contributes to MDA-MB-231 matrix degradation and is overexpressed in invasive breast tumor patients. (A) MDA-MB-231 cells were treated with indicated siRNA for SNX27 and SNX3 and codepleted of SNX1/2 or SNX5/6 and efficacy of gene silencing was detected by immunoblotting, where vinculin was used as a loading control, or qPCR (N = 3). Two-tailed Student’s t test, *** P < 0.001. Subsequently, gelatin degradation assay was performed as mentioned above and the degradation index was analyzed (N = 3, n = 250; scale bar = 10 µm). The graph represents three independent experiments; values are means ± SEM. One-way ANOVA, ** P < 0.01, *** P < 0.001. Arrowheads represent degradation dots. (B) From the publicly available database cBio Cancer Genomics Portal, various breast tumor datasets were analyzed for alteration frequency among SNX family members. (C) The SNX27 alteration frequency, types of alteration, availability of mutation analysis, and copy number alteration in the various tumor cohorts are shown. (D) SNX27 expression in normal versus invasive breast carcinoma reported in two different TCGA datasets was analyzed for fold change. (E) In the Curtis dataset, samples were separated for high and low SNX27 expression populations (n = 534). The Kaplan-Meier survival curve was plotted among these separated populations. N, number of experimental repeats.